
As Cycling And Walking Deaths Surge, Safety Experts Urge ‘Bold Action'
In the European Region, cyclist deaths surged by 50%, according to the World Health Organization. ... More When bicycle lanes aren't protected, cyclists can get hurt and even killed by car doors that are opened suddenly.
Every year, nearly 1.2 million people globally lose their lives on the roads, and as many as 50 million more are seriously injured. More than 1 of every 4 deaths occur among pedestrians and cyclists – in the European region alone, cyclist deaths surged by 50% – but only 0.2% of the roads worldwide are equipped with cycle lanes, and many communities around the world lack basic safety infrastructure like sidewalks or pedestrian crossings.
Those are just a few of the sober realities highlighted during the 8th UN Global Road Safety Week, which kicked off on Monday and continues through May 18th.
'Walking and cycling help reduce the risk of heart disease, diabetes and cancer – leading causes of premature death,' Etienne Krug, director of the World Health Organization (WHO) Department for the Social Determinants of Health, told Forbes. These most natural means of transport, he said, 'also curb air pollution, reduce traffic congestion and help fight climate change. Yet for communities to reap all these gains, we must first make walking and cycling safe.
'This is why we're calling for more urgent action,' Dr. Krug said, 'and why we're releasing a new policy toolkit to do exactly that.'
This week the WHO, the lead road safety agency for the United Nations, joins hundreds of organizations and governments worldwide to promote a shift to more walking and cycling and to make it safer and more accessible.
Under the theme 'Make walking and cycling safe,' the WHO launched 'Promoting walking and cycling: a toolkit of policy options' that presents practical guidelines and interventions designed for all sectors – from governments at all levels, international agencies, and urban planners to health advocates, businesses and schools. Included are case studies that showcase real-world examples of how these policy options are being successfully put into practice.
Dr. Krug answered questions for Forbes about the 8th edition of the UN global road safety week and the new toolkit. His responses were edited for clarity and length.
Forbes: Why is walking and cycling safety the focus this year?
Dr. Krug:. At least one pedestrian or cyclist is killed on the world's roads every 2 minutes. More than a quarter (26%) of the 1.2 million annual road traffic deaths occur among people moving by foot (21%) or bicycle (5%), yet 80% of the world's roads don't meet pedestrian safety standards and less than 1% have cycle lanes.
In addition, the danger faced by those who walk and cycle is rising in many regions. Between 2011 and 2021:
What are some highlights of this year's programming?
Hundreds of events are being planned around the world. The Global Alliance of NGOs for Road Safety, YOURS: Youth for Road Safety and several other partners are hosting events in many countries. They are also promoting use of a set of technical tools that allow people to document their experiences walking and cycling in their neighborhoods and bringing any potential dangers to the attention of local authorities. We have seen instances of this exposure leading to immediate and substantive changes, for example, to the infrastructure around specific intersections or around schools.
We are also promoting continued attention to what works to prevent road traffic deaths, including among those who walk and cycle: better laws and law enforcement, in particular around speeding, drinking and driving and using mobile phones while driving; better vehicle design, including anti-lock braking systems; better road infrastructure, such as sidewalks, crosswalks and protected bicycle lanes; and better emergency trauma care systems.
What is the goal of the new WHO toolkit?
'Promoting walking and cycling: a toolkit of policy options' calls for bold action to advance and foster safe walking and cycling. It sets out seven areas where change is needed and possible - providing guidance to policy-makers, practitioners and advocates. Examples of actions all countries and cities can implement include: setting strong frameworks by integrating walking and cycling into all relevant policy areas; investing in building safe, connected networks for walking and cycling; setting street design standards to ensure safe design and infrastructure such as sidewalks, crosswalks and protected bike lanes; ensuring safe road use by setting and enforcing safe speeds for motor-vehicles; and promoting safety through public awareness campaigns and to encourage active mobility.
What is the big take-a-way?
Walking and cycling should be the most ordinary and therefore the safest modes of transport. Leaders must prioritize making walking and cycling safe, above all, to save lives on the roads. When these modes are safe, they will also help us reap all the health, environmental and economic gains that flow from more safe walking and cycling. Many countries are taking steps in the right direction, prioritizing our right to safe mobility. Governments must continue to rethink mobility, improving safety so that people are able to make more healthy and sustainable transport choices.
For more information, click here. To access the full report, click here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
NHS set for boost of up to £30bn as other budgets feel squeeze
The NHS is expected to receive a funding boost of up to £30 billion in the spending review next week at the expense of other public services. The Department of Health is set to be handed a 2.8% annual increase in its day-to-day budget over a three-year period. The cash injection, which amounts to a rise of about £30 billion by 2028, or £17 billion in real terms, will see other areas including police and councils squeezed, The Times newspaper reported. Sir Keir Starmer has pledged to ensure that by the next election 92% of patients in England waiting for planned treatment are seen within 18 weeks of being referred. Latest NHS data suggests around 60% of people are currently seen in this time and figures released last month showed the overall number of patients on waiting lists had risen slightly from 6.24 million to 6.25 million. Chancellor Rachel Reeves has acknowledged that she had been forced to turn down requests for funding in a sign of the behind-the-scenes wrangling over her spending review. She insisted the blame for the tight economic situation lay with the Conservatives rather than her rigid rules on borrowing and spending. The Chancellor said despite a £190 billion increase in funding over the spending review period 'not every department will get everything that they want next week and I have had to say no to things that I want to do too'. On top of the increase in day-to-day spending, funded in part by the tax hikes Ms Reeves set out in her budget, looser borrowing rules will help support a £113 billion investment package. Economists have warned the Chancellor faces 'unavoidably' tough choices when she sets out departmental spending plans on June 11. The Institute for Fiscal Studies (IFS) think tank said defence and the NHS will dominate the review, raising the prospect of cuts to other unprotected departments.
Yahoo
2 hours ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
Yahoo
4 hours ago
- Yahoo
NHS app to become default source for appointments, screenings and test results
The NHS app will become the default method of communication for patients seeking appointment reminders, screening invitations and test results as part of a major investment. Millions more people will receive personal health information directly to their smartphones within the next three years in a move that is expected to save the health service £200 million, the Department of Health and Social Care said. It will also avoid the need for at least 50 million NHS letters being sent by post each year, with the Health Secretary likening the shift from analogue to digital to 'online banking or ordering a takeaway'. The £50 million investment will see 270 million messages sent through the NHS app this year, an increase of 70 million on the previous financial year. Push notifications will provide appointment reminders to patients to try to reduce the risk of no attendance, with around eight million missed appointments in elective care missed in 2023/24. More than 11 million people in the UK currently log into the NHS app every month, while almost 20 million are opted in to receive healthcare messages from the app. Where app messaging is not available, particularly for elderly patients without smartphones, communications will be sent via text message and then by letter as a last resort and phone lines will be freed up. It is hoped the changes will give patients better access to manage their healthcare journey and make informed decisions about their care. NHS app services, which were launched in December 2018, are now used in 87% of hospitals across England. Last month, NHS England announced millions of patients would be able to get 'Amazon-style' tracking updates on their prescriptions through the app, to check if their medicines are ready to collect or have been despatched for delivery. Health Secretary Wes Streeting said: 'People are living increasingly busy lives and want to access information about their health at the touch of a button, rather than having to wait weeks for letters that often arrive too late. 'This Government is bringing our analogue health service into the digital age, so that being a patient in the NHS is as convenient as online banking or ordering a takeaway. 'The NHS still spends hundreds of millions of pounds on stamps, printing, and envelopes. By modernising the health service, we can free up huge amounts of funding to reinvest in the front line. 'Through the investment and reform in our Plan for Change, we will make the NHS App the front door to the health service and put power in the hands of patients.' Rachel Power, chief executive of the Patient's Association, said: 'This major upgrade to the NHS App marks a significant step in modernising how patients receive information, from test results to screening invitations. 'This was a recommendation from our Digital Coalition and realises changes that patients have asked for. 'We welcome this investment and the ambition behind it. Success for any digital innovation will be the implementation of the Digital Inclusion Plan and working directly with patients and communities.'